ERBB2 and neoplasm: In particular, the cancer-related HER2 mutation is often used as a biomarker for 15–20% of all breast cancer tumours (Rye et al. 2018) and has been successfully targeted for gene therapy (Chung et al. 2017; Masoud and Pagès 2017).